While several studies have found a relationship for the development of pain related to one or more multiple sclerosis (MS) factors such as patient's age, duration of disease, disease course, and disability 1, 2, 3 , virtually an equal number have not 4, 5 . Pain clearly has a role in the disease as its prevalence has been reported ranging up to 74% in MS outpatients 6 . While research does implicate factors that may be related to pain, multivariate analyses are lacking, which leaves the issue unclear as to the role of the various risk factors in the development of pain 6 . The development of MS pain and its severity has implications into the general evolution of the disease which itself varies amongst the different clinical forms [relapsing-remitting-(RR), primary progressive-(PP) and secondary progressive-(SP)] as well as its gender-specific presentation. This study investigates the prevalence and severity of pain amongst multiple variables in attempt to further elucidate the role of pain within the evolution of MS. Our goal is to evaluate these results within the context of the recent mechanisms of MS that have addressed not only gender 
issues but also the relationship of relapses to long term disability and the progression of RR to SP, implicating two distinct disease phases related to late outcome. We hope to provide further insight into the relationship of pain to these end-points and its possible role in the natural history of the disease.
metHoD Procedure
In this cross-sectional clinic based study we administered a questionnaire to 100 consecutive MS patients. The questionnaire included a total of 65 questions, which included the Brazilian-portuguese validated questionnaires DN4 7 (Neuropathic Pain in 4 questions), the LANSS 8 (Leeds assessment of neuropathic symptoms and signs), Beck Depression Inventory (BDI) 9 and Anxiety (BAI) 9 , a pain questionnaire and disease related information. The survey was given to each patient at the end of their physician consult to complete independently, with no time constraints. Statistical analysis was then performed. This study was approved by the Ethics committee of the Department of Neurology at the Antonio Pedro University HospitalFluminense Federal University in Rio de Janeiro, Brazil and obtained according to the Declaration of Helsinki. Informed consent was obtained from all patients.
study sample
One-hundred consecutive MS patients met the inclusion and exclusion criteria at the Antonio Pedro University Hospital in the Department of Neuro-immunology. Inclusion criteria: diagnosis of multiple sclerosis (all clinical courses) based upon the McDonald's criteria 10 age between 18 and 80 years old, medication possession rate > 80%. Exclusion criteria: having other known neurological conditions, cancer, renal disorders, psychiatric disorder and diabetes.
Pain questionnaire
The 13 questions structured questionnaire was based on Grau-López 3 . This self-reported data evaluated the presence of pain; its location including head, upper extremities, lower extremities, back or generalized; its classification as constant or intermittent; its frequency (daily, more than 3 times per week, less than 3 times per week, or 1-3 times per month); presence of Lhermitte's phenomenon; types of head pain including migraine, tensional and trigeminal neuralgia; medication used for MS; medication used for pain.
classification of pain type
Pain was classified as either neuropathic or nociceptive. Neuropathic pain was defined as having a score of 4 or greater on the DN4 or greater than 12 on the LANSS. All other pain was otherwise classified as nociceptive.
statistical analysis
Descriptive statistics were performed to illustrate the study population demographic characteristics (gender and age) and the MS aspects (clinical form, Expanded Disability Status Scale (EDSS) medication, onset of disease and relapses) as well as the characteristics of pain (localization, type of pain, types of headache and Lhermitte's sign) and humor status (depression and anxiety). The prevalence was estimated by gender and total population. The Mann-Whitney U test was used to compare continuous variables between groups. The two-tailed Fisher's exact test and Chi-Square was used for categorical variable comparison. Logistic regression models were used to estimate the associations between pain and co-variables, such as gender, age (older or younger than 50 years old), EDSS, medication, clinical form, onset of disease, relapses, depression and anxiety. In the bivariate analysis, the variables associated with pain to significance level of 10% were included in the multivariate analysis to calculate adjusted estimates of Odds Ratio (OR). In multivariate analysis, the differences lower than 0.05 were accepted as significant. All statistical analyses were performed using program support language R (The R Foundation for Statistical Computing, Vienna, Austria; http://www.r-project.org) and SPSS 16.0 (SPSS Inc., Chicago, IL, USA).
resuLts
All 100 patients met the inclusion criteria. There were three questions that were not completed by all of the patients: presence of Lhermitte's phenomenon, 83 out of 100 responded; another two individuals did not complete the BDI (98/100) and 97/100 completed the BAI.
Descriptive statistics of prevalence rates are displayed in Table 1 . Most notably, men showed statistically higher EDSS than women (p = 0.008) with 5.4 and 3.9, respectively. The clinical forms of MS were statistically different amongst men (PP and SP) and women (RR) (p = 0.022). While women had a statistically higher prevalence of pain (p = 0.037), men had significantly higher scores on the DN4 (p = 0.016) and LANSS (p = 0.021), indicating greater severity in neuropathic pain (Table 1) . Neither depression nor anxiety was associated with the presence of pain.
The prevalence rates and gender distribution of the type of pain experienced by those patients with pain (n = 71) are shown in Table 1 . Within this group, men maintained their significantly higher EDSS than women (p = 0.056) as in the overall population. However, pain was found to be independent of EDSS (Figure 1a and 1b) . There was a significant difference in the mean number of relapses and pain in females, as seen in Figure 1 c and d (p = 0.001).
Upon comparing those patients under the age of 50 to those patients over the age of 50, we observed a statistically significant difference with younger women (under the age of 50) having a higher prevalence of pain than men and older women, whereas older men (over the age of 50) had a higher prevalence of pain than women and younger men. These results are illustrated in Figure 2 .
Logistical regression analysis found that females had a 2.7 greater chance of having pain than men (95%CI: 1.04-7) and older than 50 had only a minimal affect, 1.3 greater chance of having pain than not (95%CI: 1.07-3.2). Clinical forms showed no difference other than SP MS patients have a 67% lower risk of having pain than PP (95%CI: 0.09-1.2). However, the most indicative factor predicting the development of pain was a lower absolute number of relapses, instead of the annualized relapse rate. Excluding those with only one relapse (13/16 having PP), each relapse after the second reduced in 46% the chance of experiencing pain [OR 0.54 (95%CI:0.33-0.88)] adjusted for age and sex, but there was an interaction between sex and age as demonstrated in Table 2 -Model 1 and 2; this was found to be independent of relapse rate as shown in Figure 3 , which demonstrates the number of relapses by pain (yes or no) and by medication/treatment type. Besides, no statistical relationship was found between different medications. The complete results from the logistical analysis are demonstrated in Table 2 . We both excluded and included those patients with one relapse, and found that our results were statistically significant in both cases. There were 16 patients with one relapse, 13 of which were diagnosed with PP, one of which was diagnosed with SP and two of which had RR, one of whom was 46 years old and was painless, another 24 years old who had pain. All those with one relapse were excluded, as we did not have the MRI data and, based upon only self-reported data, we felt that including the PP and the other three patients had a greater chance of skewing the data, as there is a chance of these three cases being either PP or a clinically isolated syndrome (CIS). PP was eliminated so the data would more clearly represent the phase 1 -relapsing phase and the impact on pain.
DIscussIoN
Our population displayed similar characteristics found in other studies, including the higher prevalence among women and prevalence of pain in general. Presence of pain was independent of EDSS and had a negative association with relapses experienced. While the tendency was seen far greater in women, we believe the causes could be due to the greater number of women in our study or a gender or sex-related explanation. Though it should be noted that men showed the same trends found among women when stratified in a similar representation as showed in Figure 4 , we grouped together the sexes as the sample size is limited. Our exclusion of PP and the three cases with one relapse was to attempt to eliminate any element of confounding that could be caused by patients that may be misdiagnosed with RR-MS rather than a CIS or PP. While the statistical significance in our finding was present whether we included or excluded PP, we felt that the inclusion of PP may too strongly influence the results and as such it remained excluded from our analysis. Our results were unexpected, yet not completely out of the realm of reason and had strong support in recent MS literature. Nevertheless, we have done our due diligence in our statistical analysis, data collection, recording and interpretation to state with certainty our findings and have tried to account for any confound or aspect of the disease that may have been overlooked and that would provide an alternative hypothesis. Of course, there are always factors that cannot be controlled and should be considered when relying upon self-reported data from patients, which answers may be exaggerated and present biases such as social desirability or suggestion. We have no evidence of such a bias in our study and attempted to use the DN4, LANSS, BAI and BDI to assist in this error.
The incidence of RR-MS has been close to 2-3 times greater for women than for men, whereas the PP is a 1:1 ratio. While incidence of RR has been predominantly associated with women, severity of the disease has been linked to men. As such, the role of this gender bias has typically been considered in congruous with relapses occurring more in women than in men, though men being more severe. However, with recent studies on disability and disease progression invalidating the long held belief that relapses were indicative or related to disease/disability progression or severity, questions as to the role of relapses in MS or this first relapsing phase within the natural progression of the disease have been raised.
Our results propose that relapses are related to diminished prevalence of pain, suggesting that the first relapsing phase of MS may be protective against pain in the underlying second phase which appears to be more age-related 3, 11, 12, 13, 14 . This would imply that the increase in relapses that women undergo in their premenstrual cycle 15 , postpartum period 16 and assisted reproductive technology (ART) with gonadotropin releasing hormone agonists 17 are all indicative of the female sex related hormones/genes causing increased relapses and their surrogate lesions as a possible "protective" function by reducing pain-related brain activation in anticipation of the underlying "dormant" disease (second phase) when more debilitating progression will occur. This would also clarify the reason that more severe disability is found in men early on and greater prevalence of pain in the second phase of the disease, as it is exposure to female steroid hormones that increases the susceptibility for relapses 12 . Unfortunately, our finding remain speculative as we have found few studies on pain in multiple sclerosis and none that have stratified based upon sex.
While MRI analysis and lesion load is beyond the scope of our study, MRI T 2 or gadolinium enhancing lesions have long been established as the surrogates of focal inflammation 18 . Even though pain has been associated with various pain syndromes in MS (i.e. extremity pain, back pain, etc.), there has not been an association found between pain and the site of demyelination 19 though it has been associated with depression, spinal cord involvement at the onset and the presence of spinal cord lesions 3 . The damage to the pain pathways has been theorized to possibly involve glia and cytokines 20 , which has been linked to the possible mechanism of central pain 21 . However, no significant pain relief has been found with any of the disease modifying medications that target the immune system. Furthermore, our results are supported by recent work in neuroimaging, which suggests that intrinsic brain connectivity is associated with chronic pain intensity 22 , implying that lesions or demyelinating neurodegeneration may reduce or eliminate pain sensation. This concept directly contradicts the formerly held belief of the role of relapses and supports other work in Neurology which proposes that pain is a multimodal evaluative or distributed process in the brain 22 . Recent studies investigating brain lesions support the hypothesis that they may serve as a function of the body to reduce pain-related cortical activity 23 , or the sensory-discriminative processing of pain 23 meanwhile maintaining intact tactile thresholds 23 thus serving as a protective measure against pain or aid in its tolerability.
We postulate that with the increase of lesion load, associated with a higher number of relapses, it is possible that the interpretation of painful stimuli by the brain is impaired or that the arrival of those stimuli to somatosensorial pathways is decreased. One study 24 found that, in a long-term basis, accumulation of relapses and their consequences are less evident in patients with MS. Furthermore, with the advent of more powerful MRI scans, the confirmation of involvement of the gray matter became more sensitive. Harrison et al 25 conducted a study with 34 patients and demonstrated through 7-Tesla MRI scan that thalamic lesions were present in 24 patients. It is known that such lesions are associated with a higher EDSS score, cortical lesions and progressive forms. Regarding the thalamus as a major relay of pain, its involvement in patients with MS diminish the arrival of nociceptive inputs to cortical regions.
Studies of pain in MS patients have attempted to link the location of lesions to related pain and have found difficulty in defending this theory. For example, ongoing extremity pain is more common in patients with primary progressive or the progressive-relapsing (PR) types of MS, and lowest in the RR type 26 . MRI studies usually show plaques in the cervical and thoracic spinal cord, however the bilateral and relatively distal distribution is difficult to explain as there is ample evidence that excludes peripheral nerve involvement 5 . MS-related trigeminal neuralgia (TN) has long been attributed to a demyelinating plaque in the pons, as seen in postmortem specimens 27 , however this contrasts with the frequent neuroimaging finding of a neurovascular contact with the trigeminal root in patients with TN and MS and the existence of some patients with MS who have TN as the sole clinical manifestation and the microvascular decompression outcome of neurosurgical studies results in A representation of our population by those with and without pain stratified by number of relapses and by medication use. There was no difference amongst the use of medication as the N was very small in most cases. As the first line treatment in our clinic is Interferon, we have highlighted to represent better the trend that our results demonstrate. The N is represented at the base of each group. considerable pain relief 27 . Lhermitte's phenomenon, which is thought to come from a demyelinating plaque in the dorsal columns at the cervical level, is for many patients a transient symptom, manifesting for some weeks then resolving spontaneously 26 . Painful tonic spasms are more MS-specific. They are involuntary muscle contractions that last less than 2 minutes sometimes several times per day and usually continue for weeks or months and then disappear. They are more common in PP and SP forms and are positively correlated with age, disease duration, and disability 26 , although never found to be linked to relapses and appear to be linked to the second phase of MS.
Inasmuch as our study may provide a drastic shift in the role of relapses, it supports the recent two distinct phase model of MS 11, 24, 28 , gender 12 and age related 29 findings. However, it remains difficult to interpret drug trials, as relapses have typically been an end-point and as such creates a mind-boggling task of applying these trial results to the mechanism of action of these drugs. Even so, our results concur with several well-designed trials in SP multiple sclerosis 30 , which showed an unrelated impact of treatments focusing on focal inflammation ( frequency of relapses and MRI activity) on delaying disability progression. This implies that therapeutics focusing on these end-points rather than disability progression are actually working against the immune system to preserve the individual from later MS related pain developed in the second phase. By no means are we able to state that relapses hold a beneficial function, however our results indicate that further studies need to be done to investigate the relationship between a possibly protective role of relapses for later developed pain. As well, while we stratified our results by medication use, this is not to imply that any relationship was found in use of medication. The fact remains that our population size is extremely limited and the use of medication, pain and relapse is confounded by the specific physician choice of therapeutic treatment. Treatment choices have a variety of considerations that are unable to be stratified or listed, as they are patient specific. We stress that our results cannot be used to draw conclusion about drug treatments used and that larger longitudinal studies would be able to offer more insight. Our findings do support that the progressive phase is the core phenotype of MS, and its probability, slope, and latency should be the targets for MS treatment and investigations.
The most obvious limitation of our study is the size of our sample. While we still reached statistical significance, our findings should be verified in larger longitudinal studies and stratified per sex to verify if the same patterns exist. On this same note, as our sample was a clinic based study, it did not have an equal number of men and women, and reflects the gender bias in incidence. We believe the intensity and location of pain, though done only general in our study should be investigated in relation to the presence of MRI T 2 or gadolinium enhancing lesions. Moreover, we did not perform a regression analysis adjusted for time of disease, what we believe to be a critical limitation of study, once the greater the disease duration, the higher the relapses occurrence. Our next step will consist of analyzing the annualized relapse rate and its relationship to pain frequency. In our sample, 64 patients were on immunomodulatory therapy. Among those, 48 were in regular use of interferons. Taking into account the difficulty of MS patients to adhere to treatment, we included in our study only patients with references
